Anti-EGFR Monoclonal Antibodies for Treatment of Colorectal Cancers: Development of Cetuximab and Panitumumab. J Clin PharmacolBenoit You,Eric X. Chen.Anti-EGFR Monoclonal Antibodies for Treatment of Colorectal Cancers: Development of Cetuximab and Panitumumab[J]. Journal of Clinical Pharmacology .2012(...
This article serves to review the available evidence for anti-EGFR monoclonal antibodies and to speculate optimal strategy for their uses.doi:10.4236/jct.2012.326116Ka-On LamVictor Ho-Fun LeeScientific ResearchJournal of Cancer TherapyKa-On, LamVictor Ho-Fun, Lee. (2012) Metastatic Colorectal ...
monoclonal antibodies (eg, cetuximab, necitumumab): these bind to the extracellular component of the EGFR and prevent epidermal growth factor from binding to its own receptor, therefore preventing cell division. EGFR inhibitors may be used in the treatment of cancers that are caused by EGFR up-reg...
The anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (moAbs) cetuximab or panitumumab are administered to colorectal cancer (CRC) patients who harbor wild-typeRASproto-oncogenes. However, a percentage of patients do not respond to this treatment. In addition to mutations in theRAS...
Due to the broad importance of EGFR to tumorogenesis, targeted therapy against it has rapidly developed into a novel paradigm for cancer treatment. Two pro... WK Boland,G Bebb - 《Expert Opinion on Biological Therapy》 被引量: 233发表: 2009年 Reply: Comment on |[lsquo]|Meta-analysis of...
metastatic colorectal cancerIntroduction Monoclonal antibodies binding the EGFR, such as cetuximab and panitumumab, have been extensively used as targeted therapy for the treatment of mCRC. However, in clinical practice, it has been found that these treatment options have some limitations and fail to ...
Cancer immunotherapy employing checkpoint inhibitors holds great promise across diverse cancers; nonetheless, a substantial proportion of patients (ranging from 55 to 87%) remain unresponsive to this treatment. To amplify therapeutic efficiency, we propose a synergistic therapeutic strategy that entails the...
Two pharmacological approaches for cancer treatment have been used to block EGFR: (1) monoclonal antibodies, including cetuximab (Erbitux), panitumumab (Vectibix), and necitumumab (Portrazza); and (2) small-molecule tyrosine kinase inhibitors, including gefitinib (Iressa), erlotinib (Tarceva), ...
Epidermal growth factor receptor (EGFR) inhibitors are valuable therapeutics in metastatic colorectal cancer (mCRC). Anti-EGFR monoclonal antibodies (MoAbs), such as cetuximab or panitumumab, in combination with chemotherapy are effective treatment options for patients with RAS and BRAF wild-type mCRC...
ABN202 is an antibody-cytokine fusion protein (ACFP) that serves as a platform technology compromising the IFN-β mutein (ABN102) fused to various antibodies for specific tumor targeting. In a previous study, we designed ABN202 (αEGFR) to comprise an EGFR targeting antibody (Cetuximab) and ...